A Phase 1/2, Open-Label, Multicenter Study of Oral MRT-2359 in Patients with MYC-driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse Large B-Cell Lymphoma
NCT #
NCT05546268
Condition(s)
Lung Cancer (NSCLC), Lung Cancer (SCLC), Solid Tumor
Molecular Target(s)
GSPT1 (MYC)
Drug Classification(s)
Small Molecule
Agents(s)
MRT-2359
Phase(s)
I/II
Mechanism of Action
MRT-2359 induces degradation of GSPT1 and associated downregulation of MYC transcription factors and their transcriptional outputs, which may lead to preferential anti-proliferative activity in MYC-driven tumors.
Purpose
- How much of the study drug can be given with an acceptable level of side effects
- The effects of the study drug (good and bad)
- How much of the study drug is absorbed into the blood and how fast it is removed
- How the study drug is acting on your body
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.